Tango Therapeutics (TNGX) Current Deferred Revenue: 2020-2025
Historic Current Deferred Revenue for Tango Therapeutics (TNGX) over the last 3 years, with Jun 2025 value amounting to $23.4 million.
- Tango Therapeutics' Current Deferred Revenue fell 1.24% to $23.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $23.4 million, marking a year-over-year decrease of 1.24%. This contributed to the annual value of $17.6 million for FY2024, which is 31.37% down from last year.
- According to the latest figures from Q2 2025, Tango Therapeutics' Current Deferred Revenue is $23.4 million, which was up 19.99% from $19.5 million recorded in Q1 2025.
- Tango Therapeutics' 5-year Current Deferred Revenue high stood at $34.0 million for Q1 2023, and its period low was $15.6 million during Q3 2024.
- Over the past 3 years, Tango Therapeutics' median Current Deferred Revenue value was $23.5 million (recorded in 2024), while the average stood at $24.3 million.
- In the last 5 years, Tango Therapeutics' Current Deferred Revenue soared by 35.91% in 2023 and then plummeted by 42.37% in 2024.
- Tango Therapeutics' Current Deferred Revenue (Quarterly) stood at $26.0 million in 2021, then rose by 22.17% to $31.8 million in 2022, then dropped by 19.26% to $25.7 million in 2023, then tumbled by 31.37% to $17.6 million in 2024, then declined by 1.24% to $23.4 million in 2025.
- Its Current Deferred Revenue was $23.4 million in Q2 2025, compared to $19.5 million in Q1 2025 and $17.6 million in Q4 2024.